Pill-Only Regimens Cure Hep C
Two new pill-only regimens that rapidly cure most patients with genotype 1 hepatitis C (HCV), the most difficult to treat form of the infection, could soon be widely prescribed across Europe. Recently-published studies confirmed the efficacy and safety of combination therapy with two oral direct-acting antiviral agents (DAAs), with around 90% of patients cured after just 12-weeks of treatment.
A release from Spink Health explains that at the 22nd United European Gastroenterology Week (UEG Week October 2014) in Vienna, Austria, Professor Michael P. Manns from Hannover Medical School in Germany will presented this data and said this represents a massive step forward in the treatment of the life-threatening infection.
The release quotes Manns as saying, “These new pill-only regimens have the potential to offer more effective, safer and faster virus eradication than current therapies, even in traditionally hard-to-cure patients. We hope that a pill-only regimen will encourage more people to come forward and accept treatment so we can one day eradicate this deadly virus.”
Burden of hepatitis C infection
Hepatitis C virus (HCV) infection is a global epidemic, with more than 180 million people thought to have chronic HCV infection worldwide. HCV genotype 1 represents the majority of infections in Europe and is considered the most difficult to cure. Until recently, the standard of care for chronic HCV genotype 1 infection involved a combination of drugs, was associated with severe side-effects and involved complicated injection and tablet regimens lasting up to 1 year.
“These treatment regimens, although effective, are difficult to manage and poorly tolerated by many patients, and some clinicians won’t even use them,” says Prof. Manns. “We desperately need simpler treatment regimens that are highly effective, that can be used in more patients, and that do not cause such severe toxicity.”
New pill-only regimens
Two recently-published studies used different combinations of oral antivirals to treat patients with chronic HCV genotype 1 infection. In the first study – called the HALLMARK-DUAL study1 – 645 patients with HCV genotype 1b infection received an NS3 protease inhibitor twice-daily plus once-daily NS5A replication complex inhibitor or placebo. Twelve weeks after the end of a 24 week treatment period (the primary endpoint), the combination regimen had provided a sustained virological response (SVR) – which is considered a cure – in 90% of previously untreated patients and 82% of patients who had failed to respond to, or could not tolerate, their previous treatment.
“This is a vast improvement over standard triple therapy, with efficacy observed across the board – even in patients with liver cirrhosis and those who have failed other treatments,” says Prof. Manns. “The combination treatment was also well tolerated by most patients.”